Sònia Paytubi holds a Biology degree (1998) and a PhD in Microbiology (2004) from the University of Barcelona (UB). She obtained her PhD degree on the field of gene expression regulation in enteric bacteria.

After finishing her PhD she moved to the School of Life Sciences at the University of Dundee (Scotland, UK) where she started her postdoctoral stage studying translation regulation in eukaryotes. In 2006 she started a second postdoctoral stage at the Centre for Biomolecular Sciences at the University of St Andrews (Scotland, UK). During this postdoctoral training, funded by the Spanish Ministry of Education and Science (Fulbright/MEC Fellowship), she acquired a valuable experience on molecular biology working on the field of transcriptional regulation in Archaea. In 2009, she moved back to the UB to focus on the study of chromosomal and plasmid-encoded global modulators and their role in modulating gene expression in enteric bacteria.

Throughout her career she has been engaged in undergraduate and postgraduate teaching as Associate Professor in BSc/MSc degree programs held by the Department of Microbiology (UB). Additionally, she has supervised BSc, MSc and PhD’s theses.

In 2018 she joined the Infection and Cancer Laboratory at the Cancer Epidemiology Research Programme (PREC) in the Catalan Institute of Oncology (ICO) as a postdoctoral researcher. During the first year at ICO she also coordinated an Open-Label Phase III Clinical Trial to study the immunogenicity and tolerability of the 9-valent HPV vaccine in adult women (27 to 45 Year-Olds) compared to young adult women (16 to 26 Year-Olds) (EudraCT 2015-005093-38).

Her current interest is identifying molecular biomarkers for HPV-related cancer screening. She is Co-PI of ELAVImet, a project awarded Institute of Health Carlos III (ISCIII) (PI20/01836) where she investigates novel human and viral biomarkers to detect anal high-grade intraepithelial lesions among men that have sex with men (MSM) living with HIV. She is also focused on evaluating, through Next-Generation Sequencing and other state-of-the-art techniques, the genomic alterations in minimally invasive samples from patients with high risk of developing endometrial and ovarian cancer.